CARSGEN-B(02171): CT1190B has obtained IND approval from the National Medical Products Administration for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least second-line standard treatments.
Kojin Pharmaceutical-B (02171) announced that CT1190B, a universal CAR-T cell product targeting CD19/CD20, has obtained IND approval from the National Medical Products Administration for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least second-line standard treatment. The IIT study results of CT1190B were presented in a poster session at the 2026 European Hematology Association Annual Meeting.
CARSGEN-B (02171) announced that CT1190B, a universal CAR-T cell product targeting CD19/CD20, has obtained IND approval from the National Medical Products Administration for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least second-line standard therapy. The IIT study results of CT1190B were presented as a poster at the 2026 European Hematology Association Annual Meeting.
CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, developed based on the THANK-u Plus platform by Kehua Pharmaceutical, and is currently undergoing IIT for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Related Articles
HK Stock Market Move | WH GROUP (00288) dropped over 6% in early trading as the board meeting to discuss the mid-term results has been postponed to August 28.
HK Stock Market Move | The Pacific Shipping (02343) opened nearly 5% higher after its results, with mid-term net profit attributable to shareholders increasing by 310.35% year-on-year.
HK Stock Market Move | TRANSTHERA-B (02617) opened nearly 15% higher as its core product, Tiengobin Tablets, was approved for market release.
HK Stock Market Move | WH GROUP (00288) dropped over 6% in early trading as the board meeting to discuss the mid-term results has been postponed to August 28.
HK Stock Market Move | The Pacific Shipping (02343) opened nearly 5% higher after its results, with mid-term net profit attributable to shareholders increasing by 310.35% year-on-year.
HK Stock Market Move | TRANSTHERA-B (02617) opened nearly 15% higher as its core product, Tiengobin Tablets, was approved for market release.
RECOMMEND
